1. patients who need breathing device (for example, invasive ventilation, invasive mechanical ventilation, extra-corporeal membrane oxygenation). 2. patients who participated in other clinical trials related to covid-19. 3. patients who were administered drugs directly to covid-19 24 hours prior to the start of the study. 4. patients whose ast or alt has increased by more than 5 times the normal lab value.

1. patients who need breathing device (for example, invasive ventilation, invasive mechanical ventilation, extra-corporeal membrane oxygenation). 2. patients who participated in other clinical trials related to covid-19. 3. patients who were administered drugs directly to covid-19 24 hours prior to the start of the study. 4. patients whose ast or alt has increased by more than 5 times the normal lab value.

patients who need breathing device (for example, invasive ventilation, invasive mechanical ventilation, extra-corporeal membrane oxygenation). patients who participated in other clinical trials related to covid-19. patients who were administered drugs directly to covid-19 24 hours prior to the start of the study. patients whose ast or alt has increased by more than 5 times the normal lab value.

patients who need breathing device (for example, invasive ventilation, invasive mechanical ventilation, extra-corporeal membrane oxygenation). patients who participated in other clinical trials related to covid-19. patients who were administered drugs directly to covid-19 24 hours prior to the start of the study. patients whose ast or alt has increased by more than 5 times the normal lab value.

1. patients who need breathing device (for example, invasive ventilation, invasive mechanical ventilation, extra-corporeal membrane oxygenation). 2. patients who participated in other clinical trials related to covid-19. 3. patients who were administered drugs directly to covid-19 24 hours prior to the start of the study. 4. patients whose ast or alt has increased by more than 5 times the normal lab value.

1. patients who need breathing device (for example, invasive ventilation, invasive mechanical ventilation, extra-corporeal membrane oxygenation). 2. patients who participated in other clinical trials related to covid-19. 3. patients who were administered drugs directly to covid-19 24 hours prior to the start of the study. 4. patients whose ast or alt has increased by more than 5 times the normal lab value.